首页> 外文期刊>Brain & Development >Serum total amylase, pancreatic amylase and lipase activities in epileptic children treated with sodium valproate monotherapy.
【24h】

Serum total amylase, pancreatic amylase and lipase activities in epileptic children treated with sodium valproate monotherapy.

机译:丙戊酸钠单药治疗的癫痫患儿的血清总淀粉酶,胰淀粉酶和脂肪酶活性。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

To investigate by a prospective, self-controlled method, whether early treatment with sodium valproate (VPA) monotherapy has some effect on serum total amylase and particularly on its pancreatic isoenzyme and lipase activities in epileptic children. Serum total amylase, pancreatic amylase and lipase activities have been evaluated in 23 epileptic children, before and at 6 and 12 months of VPA monotherapy. All children remained without clinical symptoms of pancreatitis during the period of study. Serum pancreatic amylase activities were significantly decreased at 6 and 12 months of treatment with VPA, whereas serum total amylase and lipase activities did not show any significant changes at 6 or 12 months of treatment. Non-pancreatic isoenzyme activities of amylase were significantly higher at 6 and 12 months of treatment. Three patients (13%) had slightly elevated serum total amylase levels at 6 and 12 months of treatment. There was no significant correlation of serum pancreatic amylase levels or non-pancreatic isoenzyme levels of amylase with serum VPA levels at 6 and 12 months of treatment. Non-pancreatic amylase activities, probably derived from salivary glands, may be increased in children treated with VPA monotherapy. Measurement of serum pancreatic amylase and/or serum lipase activities is indicated in patients with increased serum total amylase levels but without clinical symptoms of pancreatitis and, furthermore, in patients with symptoms suggesting dysfunction of pancreas, in order to avoid unnecessary discontinuing of VPA.
机译:为了通过前瞻性,自我控制的方法进行调查,早期使用丙戊酸钠(VPA)单药治疗是否对癫痫患儿的血清总淀粉酶,特别是其胰同工酶和脂肪酶活性有一定影响。在VPA单药治疗的6个月和12个月之前,6个月和12个月时,已经评估了23名癫痫患儿的血清总淀粉酶,胰淀粉酶和脂肪酶活性。在研究期间,所有儿童均无胰腺炎的临床症状。用VPA治疗6和12个月时,血清胰腺淀粉酶活性显着降低,而治疗6或12个月时,血清总淀粉酶和脂肪酶活性未显示任何显着变化。淀粉酶的非胰腺同工酶活性在治疗6个月和12个月时显着更高。 3名患者(13%)在治疗6个月和12个月时血清总淀粉酶水平略有升高。治疗6个月和12个月时,血清胰淀粉酶水平或淀粉酶非胰同工酶水平与血清​​VPA水平无显着相关性。 VPA单一疗法治疗的儿童可能会增加唾液腺产生的非胰淀粉酶活性。在血清总淀粉酶水平升高但无胰腺炎临床症状的患者中,以及在有暗示胰腺功能障碍的症状的患者中,应测定血清胰腺淀粉酶和/或血清脂肪酶活性,以避免不必要的VPA停药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号